Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 858.00K.
Subavaliada
O PE mais recente da empresa é -11.69, em uma faixa percentil baixa de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 3.48M ações, uma redução de 10.59% em relação ao trimestre anterior.
Mantido por Andreas Halvorsen
O Super Investidor Andreas Halvorsen possui 323.47K ações desta empresa.
Baixa Atividade de Mercado
A empresa tem menor interesse dos investidores, com uma taxa de giro de 20 dias de -0.86.